IOL Chemicals & Pharmaceuticals Ltd.

As of June 30, 2026, IOL Chemicals & Pharmaceuticals Ltd. carries a market capitalization of 42.65B, placing it among publicly traded companies globally. Its enterprise value stands at 42.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IOL Chemicals & Pharmaceuticals Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, IOL Chemicals & Pharmaceuticals Ltd. has 293.53M shares outstanding.

As of June 30, 2026, IOL Chemicals & Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 25.40.

As of June 30, 2026, IOL Chemicals & Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 14.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 42.65B versus a market cap of 42.65B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 7.25M in revenue per employee across its workforce of 3,479.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, IOL Chemicals & Pharmaceuticals Ltd. recorded 574.30M in income tax expense. That works out to an effective tax rate of 25.46, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.26B, leaving 1.68B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, IOL Chemicals & Pharmaceuticals Ltd.'s stock has gained approximately 80.09% over the past 52 weeks. The 50-day moving average sits at 191.16, while the 200-day moving average is 126.24.

Over the twelve months ended June 30, 2026, IOL Chemicals & Pharmaceuticals Ltd. generated 25.24B in revenue and converted that into 1.68B in net income, yielding earnings per share of 5.72. EBITDA reached 2.99B, while operating income came in at 2.29B.

Over the twelve months ended June 30, 2026, IOL Chemicals & Pharmaceuticals Ltd. posted a gross margin of 36.57, reflecting its pricing power and cost economics. The operating margin of 9.06 and net profit margin of 6.66 provide insight into operational efficiency.

IOL Chemicals & Pharmaceuticals Ltd.'s most recent stock split took place on March 11, 2025 with a 1:5 split ratio.